Urology Specialists of West Florida

Urology Specialists of West Florida, LLP (“USWF”) is the largest urology practice in greater St. Petersburg / Clearwater and is a leading provider of radiation therapy treatment in West Florida through its Radiation Oncology Center (the “Center”). USWF has operated its Center in Clearwater, FL since March 2009 and provides a comfortable experience to prostate cancer patients while delivering the highest quality of care. Prior to the transaction, the Center was wholly owned by USWF.

McKesson Specialty Health, through its wholly owned US Oncology / Vantage Oncology subsidiaries, develops and operates radiation oncology centers of excellence through acquisitions and joint ventures. The company seeks to address the growing need among cancer patients, hospitals and physicians for easily accessible and advanced radiation treatment therapies. McKesson Specialty Health operates over 140 treatment facilities in 25 states, and has a network of providers which includes 200 Urologists, 250 Radiation Oncologists and 800 Medical Oncologists.

As a result of the transaction, USWF and McKesson plan to grow high quality radiation therapy services in West Florida through a combination of strategic insight, application of clinical best-practices and a patient-centered approach.

Cypress Associates LLC acted as financial advisor to USWF in the sale of its radiation assets to a new company jointly owned by USWF and McKesson.

nPhase Inc

nPhase, Inc. is a SaaS-based software company formed to commercialize a cloud-enabled, Part 11 certified clinical trials management software solution using Vanderbilt University’s world renown, server-based REDCap electronic data capture application which collects, manage and reports data for clinical research trials.

At transaction closing, REDCap had approximately 300,000 users at 1,500 institutions, including many of the most well-known academic research organizations in the world (e.g., Harvard, Yale, Stanford, Johns Hopkins, Duke, Mayo Clinic, Cleveland Clinic, Children’s Hospital of Philadelphia, Vanderbilt).

In 2015, nPhase was selected by Vanderbilt to perform REDCap’s software enhancements and bring to market the FDA-certified clinical trials management software solution. nPhase operates under a long-term, exclusive worldwide license granted by Vanderbilt.

In December 2015, with the assistance of Cypress, nPhase successfully structured and closed a private placement of Series A Convertible Preferred Stock purchased by WRD Capital, Selous Ventures, Solidus, and Vanderbilt University.

Cypress acted as placement agent to nPhase in connection with the Company’s equity financing transaction.

In the course of the transaction, Cypress also provided value-add financial advisory expertise, including negotiating key terms of the transaction such as governance provisions and investor voting rights.

Vector Oncology

Vector Oncology is a leader in the design and delivery of care based Health Economics and Outcomes Research (HEOR) and data analytics in oncology. Headquartered in Memphis, Vector Oncology utilizes its comprehensive Oncology Data Warehouse and proprietary Patient Care Monitor patient engagement and outcomes platform to design deliver high quality projects generating real world evidence and insight. Prior to the transaction, the Contract Research Organization(CRO) business unit was also wholly owned by the Company.

George Clinical is a leading Asia-Pacific based clinical research organization with global capabilities differentiated by scientific leadership and extensive site networks. Headquartered in Australia, George Clinical has a staff operating in 11 countries, and provides the full range of clinical trial services to pharmaceutical, medical device and biotech customers for all trial phases, registration and post-marketing trials. George Clinical’s parent organization, The George Institute for Global Health, is a leader in chronic disease research with a global network of experts with whom George Clinical engages.

The sale transaction provides Vector Oncology’s CRO with the ability to accelerate its international growth in oncology and to expand to other therapeutic areas. The acquisition enables George Clinical to expand its robust operational expertise and scientific leadership in vascular, renal and respiratory diseases, neurology and endocrinology throughout the United States.

Cypress Associates LLC acted as financial advisor to Vector Oncology in the sale of its CRO division to George Clinical.

nPhase Inc

nPhase, Inc. is a SaaS-based software company which sells REDCap Cloud, a cloud-enabled, Part 11 certified clinical trials management software solution, to healthcare organizations deploying patient engagement-focused data capture strategies.

REDCap Cloud is used by pharmaceutical companies and contract research organizations (CROs) to collect, manage and report data for clinical research trials to be filed with the FDA and by healthcare providers to capture other patient-related data (such as patient reported outcomes data used for value-based pricing models).

REDCap Cloud was launched commercially in the fall of 2016 and uses (via an exclusive license) Vanderbilt University’s world renown, server-based REDCap electronic data capture application as its foundation. REDCap Cloud has established a solid and quickly growing customer base of pharmaceutical companies, CROs and other healthcare providers.

At transaction closing, REDCap’s Vanderbilt consortium(using the server-based software) was comprised of approximately 560,000 users at 2,400 institutions, including many of the most well-known academic research organizations in the world (e.g., Harvard, Yale, Stanford, Johns Hopkins, Duke, Mayo Clinic, Cleveland Clinic, Children’s Hospital of Philadelphia, Vanderbilt).

In May 2017, with the assistance of Cypress, nPhase successfully structured and closed a follow-on private placement of Series B Convertible Preferred Stock purchased by existing investors, including WRD Capital and Vanderbilt University.

In December 2015, with the assistance of Cypress, nPhase successfully structured and closed a private placement of Series A Convertible Preferred Stock purchased by WRD Capital, Selous Ventures, Solidus, and Vanderbilt University.

Cypress acted as placement agent to nPhase in connection with its Series A and Series B equity financing transactions.

HCA

HCA is one of the leading health care service companies in the United States. HCA owns and operates approximately 179 hospitals and approximately 104 freestanding surgery centers in 21 states, England and Switzerland.

Cypress was retained by HCA to analyze certain issues regarding the sale process and the valuation of its going private transaction. At the time the transaction closed in November 2006, it was the largest leveraged buyout in history.

Amylin

Amylin Pharmaceuticals makes and markets two injectable diabetes drugs, Byetta and Symlin, that are approved as adjunct therapies to other diabetes treatments such as metformin and insulin. Amylin’s US-based sales force co-promotes Byetta with Eli Lilly and markets Symlin on its own. The company is working on other diabetes drugs, including a once-weekly version of Byetta, as well as treatments for obesity.

The San Antonio Fire & Police Pension Fund provides comprehensive retirement, death and disability benefits for the City of San Antonio’s approximately 5,377 police officers, fire fighters, retirees and their beneficiaries. They are an investor in Amylin.

Case description: Alleged breaches of fiduciary duty by the Board of Directors of Amylin arising from their adoption of defensive measures in two debt instruments.

Cypress acted as consultants to San Antonio Fire & Police as to customary terms of bank loans and convertible debentures and market conditions for debt issuance. Oral arguments were heard on September 30, 2009 concerning Plaintiff’s appeal of the Court’s ruling denying summary judgment.

MMIS

MMIS, Inc. is a leading SaaS-based enterprise global compliance software company to the pharmaceutical and medical device industry internationally. The Company’s product suite is comprised of high value-added business collaboration and compliance software modules which create a unique end-to-end solution.

The Company’s compliance solutions are in high demand from clients due to the current requirements for pharmaceutical and medical device companies to comply with “open payments” regulations under The Sunshine Act in the U.S. and similar regulations globally. MMIS, Inc. pursued an equity financing to further accelerate its growth and capitalize on the favorable market environment for its services.

With the assistance of Cypress, MMIS, Inc. successfully structured and executed a private placement of Series A-1 Convertible Preferred Stock purchased by EDG Partners Fund II, L.P.

Cypress acted as the exclusive placement agent to MMIS, Inc. in connection with the Company’s growth equity recapitalization transaction.

In the course of the transaction, Cypress also provided value-add financial advisory expertise, including negotiating the valuation used to determine EDG’s pro forma equity ownership in the recapitalized company and developing the strategy to redeem all outstanding shares from owners of the Company’s previously outstanding preferred stock.

StoneMor

Cypress Associates LLC is pleased to announce that the firm acted as financial advisor to StoneMor GP LLC, the general partner of StoneMor Partners L.P. (NYSE: STON) (“StoneMor Partners”), in connection with two transactions with American Cemeteries Infrastructure Investors, LLC (“ACII”), an affiliate of American Infrastructure MLP Funds. The first transaction was ACII’s purchase, directly and indirectly, of a majority of the membership interests of StoneMor GP LLC from certain unitholders. The second transaction was ACII’s purchase of $55 million in StoneMor Partners common units to fund the long-term lease agreement of 13 cemeteries owned by the Archdiocese of Philadelphia. Dividends on the common units are, at the option of StoneMor GP, payable in registered common units rather than cash for up to four years. Cypress Associates LLC rendered fairness opinions in connection with both transactions and both transactions closed on May 21, 2014.

StoneMor Partners L.P. headquartered in Levittown, Pennsylvania, is an owner and operator of cemeteries and funeral homes in the United States, with 278 cemeteries and 90 funeral homes in 28 states and Puerto Rico. StoneMor is the only publicly-traded deathcare company structured as a master limited partnership.

Urology of Indiana

Cypress Associates LLC is pleased to announce the completion of the sale of Urology of Indiana’s radiation assets to a new company jointly owned by Urology of Indiana, LLC (UOI) and Vantage Oncology, LLC (Vantage). As a result of the transaction, UOI and Vantage plan to grow high quality radiation therapy services in the state of Indiana through a combination of strategic insight, application of clinical best- practices and a patient centered approach.

Urology of Indiana, LLC is the largest urology practice in greater Indianapolis and is a leading provider of radiation therapy treatment in the state of Indiana through its two Centers for Prostate Cancer (CPCs). UOI has operated CPCs in Indianapolis since 2006 and provides a comfortable experience to prostate cancer patients while delivering the highest quality of care. Prior to the transaction, the CPCs were wholly owned by UOI.

Founded in 2002, Vantage Oncology, LLC develops and operates radiation oncology centers of excellence through acquisitions and joint ventures. The company seeks to address the growing need among cancer patients, hospitals and physicians for easily accessible and advanced radiation treatment therapies. Vantage Oncology currently operates 63 treatment facilities in 15 states.

As a result of the transaction, UOI and Vantage plan to grow high quality radiation therapy services in the state of Indiana through a combination of strategic insight, application of clinical best- practices and a patient centered approach. Cypress Associates LLC acted as financial advisor to UOI in the sale of its radiation assets to a new company jointly owned by UOI and Vantage.

Columbus Prostate Cancer Center

Columbus Prostate Cancer Center, LLC (CPCC) is a leading provider of radiation therapy treatment in Central Ohio. CPCC has operated in Columbus, Ohio since 2008 and provides a comfortable experience to prostate cancer patients while delivering the highest quality of care. Prior to the transaction, CPCC’s majority owner was Central Ohio Urology Group, Inc. (COUG), the largest urology practice in greater Columbus.

Founded in 2002, Vantage Oncology, LLC develops and operates radiation oncology centers of excellence through acquisitions and joint ventures. The company seeks to address the growing need among cancer patients, hospitals and physicians for easily accessible and advanced radiation treatment therapies. Vantage Oncology currently operates 47 treatment facilities in 12 states.

As a result of the transaction, COUG and Vantage plan to grow high quality radiation therapy services in Central Ohio through a combination of strategic insight, application of clinical best-practices and a patient centered approach.

Cypress Associates LLC acted as financial advisor to CPCC in the sale of its assets to COUG and Vantage.